ATC免疫刺激的概念超越了CD47，如今研究人员已经开发了新型策略，其能靶向作用其它肿瘤特异性受体来制造ADCs，从而促使机体针对多种难以治疗的癌症。研究人员的目标是在未来三至五年内为临床试验做好首批准备。综上，本文研究结果表明，设计ATCs来促进机 ...

*仅供医学专业人士阅读参考我们知道，在一些血液系统恶性肿瘤中，HDAC抑制剂（HDACi）表现出了不错的疗效，但在实体瘤方面，HDACi的疗效确实有点不尽如人意，这与其耐药问题有关。既往有研究显示，肿瘤微环境的改变可能是导致HDACi耐药的一个因素， ...

为了揭开这个谜团，找到提高 HDACis 疗效的方法，湖州师范学院第一附属医院和浙江大学医学院附属邵逸夫医院等单位的研究人员进行了深入研究，并在《Journal of Experimental & Clinical Cancer Research》期刊上发表了题为 “Macrophage infiltration and CD47 upregulation mediate ...

2月25日，最新发表在Nature Cancer杂志上的一项研究中，来自德克萨斯大学MD Anderson癌症中心的科学家们开发出了一种新型的抗体-毒素偶联物（antibody-toxin conjugate, ATC），用以刺激免疫系统来根除肿瘤。ATC技术结合了ADC及免疫疗法，有望为癌症患者带来新的治疗选择。

Simplified, the CD47 antibody binds to cancer cells, marking them to be eaten by the body's immune cells. Once the immune cells engulf the tumor, the toxin is released inside, becoming activated and ...

ALX Oncology is laying off 30% of its workforce as the biotech seeks to channel its cash into further trials of its CD47 ...

Simplified, the CD47 antibody binds to cancer cells, marking them to be eaten by the body's immune cells. Once the immune cells engulf the tumor, the toxin is released inside, becoming activated ...

Simplified, the CD47 antibody binds to cancer cells, marking them to be eaten by the body’s immune cells. Once the immune cells engulf the tumor, the toxin is released inside, becoming activated ...

Wen Jiang, M.D., Ph.D., Associate Professor of Radiation Oncology, University of Texas MD Anderson Cancer Center Many solid tumors express the CD47 protein on their surface, which serves as a "don ...

“In 2024, we delivered strong progress and continued momentum for our clinical development program evaluating evorpacept as a ...

As the global cancer crisis intensifies, the demand for breakthrough treatments is reaching new heights. Statista data ...